Tested Applications
| Positive WB detected in | K-562 cells, MCF-7 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
14101-1-AP targets PRR13 in WB, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag5280 Product name: Recombinant human PRR13 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-148 aa of BC066943 Sequence: MWNPNAGQPGPNPYPPNIGCPGGSNPAHPPPINPPFPPGPCPPPPGAPHGNPAFPPGGPPHPVPQPGYPGCQLLGPYPPPYPPPAPGIPPVNPLAPGMVGPAVIVDKKMQKKMKKAHKKMHKHQKHHKYHKHGKHSSSSSSSSSSDSD Predict reactive species |
| Full Name | proline rich 13 |
| Calculated Molecular Weight | 15.2 kDa |
| Observed Molecular Weight | ~20 kDa |
| GenBank Accession Number | BC066943 |
| Gene Symbol | PRR13 |
| Gene ID (NCBI) | 54458 |
| RRID | AB_2878012 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9NZ81 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
PRR13, also named as TXR1, is reported to be a key regulator of the resistance to cytostatica by decreasing the copy number of the proapoptotic gene thrombospondin-1. PRR13 has some isoforms with MW 10 kDa, 15-17 kDa and 19-23 kDa.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for PRR13 antibody 14101-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The antibody anti-GAPDH (Catalog No. 14101-1-AP) has 1 total citation. It appears in the journal Onco Targets Ther (Impact Factor 2.4), published in June 2020. The associated research field is oncology, specifically investigating Connexin 43's role in modulating paclitaxel resistance via β-tubulin targeting in triple-negative breast cancer. The antibody was applied in Western Blot (WB) on human samples.
| Species | Application | Title |
|---|---|---|
